Study: Cannabis Agonists Produce Anti-Cancer Effects In Human Liver Cancer Cells

Tehran, Iran: The administration  of synthetic cannabinoid agonists reduce cell viability in human hepacarcinoma  cells and may be a potential option for the treatment of liver cancer,  according to preclinical data published online in the journal Toxicology Mechanisms and Methods.

Investigators  from the Tehran  University of Medical Sciences, Department of Toxicology and Pharmacology  assessed the anti-cancer properties of two synthetic cannabinoids, CB65 (CB2 receptor agonist) and  ACEA (CB1 receptor agonist) in human hepacarcinoma cells.

Authors  reported that the administration of cannabinoids reduced malignant cell  viability and cell invasion in a dose-dependent manner. “These data suggest ACEA and CB65 as an option for novel  treatment of hepatocellular cancer,” they concluded.

Previous studies have demonstrated that cannabinoids inhibit  tumor cell growth and selectively induced apoptosis by different cell signaling  pathways in various types of malignant cells, including gliomas (brain cancers)  and lymphomas, prostate, breast, lung, skin, and pancreatic cancer cells.

For  more information, please contact Paul Armentano, NORML Deputy Director, at: Full text of the study, “Evaluation of Anti-invasion Effect of Cannabinoids  on Human Hepatocarcinoma Cells,” is available in Toxicology Mechanisms and Methods.

Leave a Reply